BioMarin Pharmaceutical Inc. (BMRN) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Uneven Profitability ⢠Rich Valuation BMRN has strong liquidity, low leverage, and solid cash flow, but inconsistent quarterly profitability and a rich valuation make execution the key risk.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Near support ⢠Weak momentum Support Level: $53.00 to $53.20 Resistance Level: $54.80 to $55.50 BMRN has drifted lower over the last month, with fading rebounds and lower highs keeping near-term momentum weak as it tests support around $53.00â$53.20.
Sentiment & News
Key News Insights: ⢠VOXZOGO upside ⢠Leadership transition ⢠Stock weakness BioMarin (BMRN) is being framed as a potential rebound story on VOXZOGO-led rare-disease upside, even as a board chair transition adds a governance change overlay to the investment case.
AI Summary
BioMarin now looks less like a one-drug growth story and more like a cash-generative rare-disease platform, but the stock will increasingly hinge on whether VOXZOGO can keep compounding fast enough to offset maturation/competition and whether new drivers can prove themselves before growth decelerates.
Description
BioMarin Pharmaceutical is a biopharmaceutical company that develops and sells therapies for rare and serious genetic and metabolic disorders, with marketed treatments across lysosomal storage disorders, phenylketonuria, Batten disease, achondroplasia and related conditions. Its late-stage pipeline includes gene therapies for hemophilia A and phenylketonuria and early-stage programs for primary hyperoxaluria, while commercial operations distribute products through specialty pharmacies, hospitals and wholesalers in the U.S., Europe, Latin America and other markets. The company maintains multiple licensing and collaboration arrangements and is headquartered in San Rafael, California, having been founded in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 22 | Dec 29 | BMRN | BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum. | Closed | +1.3% |